Protalix Biotherapeutics Inc (PLX)
Official siteHEALTHCARE • BIOTECHNOLOGY • AMEX
Market Cap: $257.17M
Last updated: Nov 17, 2026 at 11:05 AM ET
Protalix Biotherapeutics Inc (PLX) P/E Ratio & Valuation History
Protalix Biotherapeutics (PLX) trades at 12.1x trailing earnings and 2.9x sales. Its P/S of 2.9x is above its 5-year median of 1.8x. Its forward P/E is 61.0x.
Current Multiples
Its forward P/E is above its trailing P/E, which implies earnings per share about 80.2% lower over the next year. Its free cash flow yield is 6.2%.
| Multiple | Value |
|---|---|
| P/E (trailing) | 12.1x |
| Forward P/E | 61.0x |
| Price to sales | 2.9x |
| Price to book | 3.0x |
| EV/EBITDA | 8.0x |
| Price to FCF | 16.1x |
| EV/FCF | 14.7x |
| PEG | N/A |
| FCF yield | 6.2% |
Historical Medians
Against its 10-year medians, its P/S is 45.0% above 2.0x.
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/S | 2.9x | 1.8x | 2.0x |
Valuation History
Over the 9 of the 10 year ends shown that have a P/S, its P/S ranged from 0.9x in 2019 to 214.3x in 2018.
| Year end | Price | P/E | P/S | P/B |
|---|---|---|---|---|
| 2025 | $1.80 | N/A | 2.7x | 2.9x |
| 2024 | $1.88 | 62.7x | 2.7x | 3.5x |
| 2023 | $1.78 | 29.7x | 1.8x | 3.9x |
| 2022 | $1.37 | N/A | 1.4x | N/A |
| 2021 | $0.83 | N/A | 0.9x | N/A |
| 2020 | $3.63 | N/A | 1.9x | N/A |
| 2019 | $3.28 | N/A | 0.9x | N/A |
| 2018 | $3.11 | N/A | 214.3x | N/A |
| 2017 | $6.61 | N/A | N/A | N/A |
| 2016 | $4.45 | N/A | 1.9x | N/A |
GNG Valuation
| GNG view | Fairly valued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About PLX
What is PLX's forward P/E ratio?
Protalix Biotherapeutics has a forward P/E ratio of 61.0x.
Is PLX stock overvalued?
GNG's valuation label for PLX is Fairly valued.
What is PLX's price to sales ratio?
Protalix Biotherapeutics has a price to sales ratio of 2.9x.
PLX pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors